Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
2 clinical trials · Condition
◉ Watch Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
| Record | Firm | Date |
|---|---|---|
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas (NCT06716658) | Institute of Hematology & Blood Diseases Hospital, China | 2024-12-25 |
| A Registry for People With T-cell Lymphoma (NCT05978141) | Memorial Sloan Kettering Cancer Center | 2023-07-27 |
Track Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract automatically
Every clearance here is in the API, with alerts when new ones post.